Effectiveness and framing of pharmaceutical opioid abuse-deterrent formulations.
Where this comes from
- Record sourced from PubMed, PMID 30767388.
- Also identified by DOI 10.1111/add.14556 and PMC identifier 6656581.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Abuse-deterrent formulations (ADFs) of pharmaceutical opioids have limited capacity to reduce extra-medical use and harm; their impact is likely restricted to prevention of specific practices among population sub-groups. This debate highlights the importance of viewing ADFs as one component in a range of public health responses. Greater involvement of invested parties (e.g., prescribers, consumers) and reframing terminology will reduce discrimination and stigma.
Medical subject headings
- Abuse-Deterrent Formulations
- Opioid-Related Disorders
- Prescription Drug Misuse